



**HAL**  
open science

## **Vertebroplasty versus bracing in acute vertebral compression fractures: A prospective randomized trial**

Emmanuel Chabert, Eulalie Hugonnet, Adrian Kastler, Laurent Sakka, Francis Abed Rabbo, Abderrahim Zerroug, Emmanuel Coudeyre, Bruno Pereira, Guillaume Coll

### ► To cite this version:

Emmanuel Chabert, Eulalie Hugonnet, Adrian Kastler, Laurent Sakka, Francis Abed Rabbo, et al.. Vertebroplasty versus bracing in acute vertebral compression fractures: A prospective randomized trial. *Annals of Physical and Rehabilitation Medicine*, 2023, 66 (6), pp.101746. <10.1016/j.rehab.2023.101746>. <hal-04126473>

**HAL Id: hal-04126473**

**<https://hal.science/hal-04126473v1>**

Submitted on 9 Jul 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC 4.0 - Attribution - Non-commercial use - International License

**Vertebroplasty versus bracing in acute vertebral compression fractures:  
a prospective randomized trial.**

Emmanuel Chabert, MD<sup>a</sup>; Eulalie Hugonnet, MD<sup>b</sup>, Adrian Kastler, MD, PhD<sup>c</sup>, Laurent Sakka, MD, PhD<sup>d</sup>, Francis Abed Rabbo, MD<sup>d</sup>, Abderrahim Zerroug, MD<sup>a</sup>, Emmanuel Coudeyre, MD, PhD<sup>e</sup>, Bruno Pereira<sup>f</sup>, Guillaume Coll, M.D, PhD<sup>d</sup>

<sup>a</sup>Service de Neuroradiologie, Centre Hospitalier Universitaire de Clermont-Ferrand, 58 rue Montalembert, 63 000 Clermont-Ferrand, France

<sup>b</sup>Service de Radiologie, Hôpital de Vichy, Boulevard Denière, 03200 Vichy, France

<sup>c</sup>Service de Neuroradiologie, Centre Hospitalier Universitaire de Grenoble-Alpes, Avenue des Maquis du Grésivaudan, 38700 La Tronche, France ;

<sup>d</sup>Service de Neurochirurgie B, Centre Hospitalier Universitaire de Clermont-Ferrand, 58 rue Montalembert, 63 000 Clermont-Ferrand, France ;

<sup>e</sup>Service de médecine physique et réadaptation, Centre Hospitalier Universitaire de Clermont-Ferrand, 58 rue Montalembert, 63 000 Clermont-Ferrand, France

<sup>f</sup>Délégation à La Recherche Clinique et à L'Innovation, Centre Hospitalier Universitaire de Clermont-Ferrand, 58 rue Montalembert, 63 000 Clermont-Ferrand, France

Conflict of Interest: None.

Funding: None.

Corresponding Author:

Guillaume Coll

Centre Hospitalier Universitaire de Clermont-Ferrand, 58 rue Montalembert, 63 000 Clermont-Ferrand, France.

Mail: [gcoll@chu-clermontferrand.fr](mailto:gcoll@chu-clermontferrand.fr)

**Vertebroplasty versus bracing in acute vertebral compression fractures:  
a prospective randomized trial.**

**ABSTRACT**

**Background.** The treatment of stable vertebral compression fractures remains controversial.

**Objective.** To compare the efficacy of vertebroplasty and bracing for acute vertebral compression fractures.

**Methods.** We conducted a prospective, randomized, non-blinded, single-center study. Adult participants were randomized to undergo vertebroplasty or bracing. Both groups were stratified by age. The primary outcome was functional disability (Roland-Morris disability questionnaire [RMDQ]). Secondary outcomes were pain intensity (Visual Analogue Scale [VAS]), and change in vertebral body height and kyphosis angle. Outcomes were assessed on day 2, and 1, 3 and 6 months after treatment.

**Results.** Ninety-nine people were included, 51 in the vertebroplasty group and 48 in the brace group. Treatment was performed within 2 weeks of the trauma. On day 2 post-treatment, pain was lower in the vertebroplasty group (mean [SD] 2.3 [1.5] versus 3.4 [2.1],  $p=0.004$ ) but the difference was no longer significant at 6 months. Functional disability was significantly lower in the vertebroplasty than brace group at all time-points (RMDQ score 7.5 [5.7] vs 11.4 [5.3],  $p<0.001$  at 1 month). At 6 months, the increase in kyphosis angle was smaller in the vertebroplasty than the brace group ( $+1.5^\circ$  versus  $+4^\circ$ ,  $p<0.001$ ).

**Conclusion.** In people with acute vertebral compression fractures, the immediate effect of vertebroplasty was greater than that of bracing on pain and function, and for restoring sagittal balance. At 6 months, the superiority of vertebroplasty decreased, except for the maintenance of sagittal balance.

**Database Registration:** ClinicalTrials.gov number, NCT01643395

**Keywords:** vertebroplasty; vertebral fracture; kyphoplasty; kyphosis angle; thoraco-lumbo-sacral orthoses; brace

## **Abbreviations**

LKA local kyphosis angle

MCS mental component summary

PCS physical component summary

RMDQ Roland-Morris disability questionnaire

SF36 Medical Outcome Study Short Form-36

STIR short-tau inversion recovery

TLSO thoraco-lumbo-sacral orthoses

VAS visual analog scale

## **INTRODUCTION**

Treatment for acute vertebral compression fractures with no neurological deficit or spinal instability is not consensual. Therapeutic options include passive observation, bracing, kyphoplasty or surgery [1-3]. Previous studies with small sample sizes failed to demonstrate whether surgery is superior to bracing and whether bracing is superior to passive observation [4-6]. Although a growing number of individuals are treated by kyphoplasty or vertebral expansion techniques, these techniques have never been assessed in randomized controlled trials [7-9]. Several non-randomized studies yielded promising results for vertebroplasty in acute compression fractures [10-12]. However, vertebroplasty has never been compared to bracing for this indication in randomized studies. The aim of our study was to compare the efficacy of vertebroplasty and conservative treatment by bracing for the treatment of acute compression fractures in adults.

## **METHODS**

### **Trial design**

VOLCANO was a prospective, randomized, non-blinded, single-center trial comparing conservative treatment (brace) and vertebroplasty for acute vertebral compression fracture type A according to the Magerl classification. The study was conducted between 2010 and 2013 at the University Hospital of Clermont-Ferrand. In case of failure of the assigned treatment, participants were offered the other treatment and were considered as crossovers. The study is reported according to the CONSORT guidelines for randomized trials of non-pharmacologic treatments [13].

### **Ethical considerations**

VOLCANO (registration number 2010-A00332-37) received ethical approval from the Comité de Protection des Personnes Sud Est (Committee for the Protection of People South-East, ref 2010-17) as well as an authorization from the Agence Française de Sécurité Sanitaire du Médicament et des Produits de Santé (French Agency for the Safety of Health Products, ref UEC/LynAB/DA/2010 -152). All participants provided written informed consent for participation.

### **Participants**

Participants were enrolled by 1 of 2 investigators, a neurosurgeon or a neuroradiologist. Inclusion criteria were aged  $\geq 18$  years, spinal trauma of  $<15$  days, and type A Magerl traumatic vertebral compression fracture below T5. Trauma was defined as any damage caused by a sudden physical injury secondary to an impact or a fall from a height  $\geq$  the individual's height. Before treatment, a CT-scan and an MRI with short-tau inversion recovery sequencing (STIR) were performed. Only vertebrae with STIR hyperintensity were considered for inclusion since acute vertebral compression fractures present an increased bone marrow edema resulting in intraosseous STIR hyperintensity [14].

The exclusion criteria were vertebral arch fracture, retropulsed bone fragments with vertebral canal narrowing  $>50\%$  in the lumbar and  $>30\%$  in the thoracic spine, neurological deficit,

inability to provide informed consent, long-term analgesia, infection, malignancy, coagulation disorder, contraindication to general anesthesia, and pregnancy.

## **Interventions and procedures**

### **Vertebroplasty**

Procedures were performed by experienced interventional neuroradiologists under general anesthesia and prophylactic antibiotic treatment. All vertebroplasties were performed according to a standardized protocol. Participants were positioned prone on a fluoroscopy biplane examination table. Pillows were inserted under the chest and pelvis to increase the lordosis. A unilateral extrapedicular approach was performed after a 2% lidocaine injection. An 11 G trocar was pushed toward the ventral third of the vertebral body under bi-plane fluoroscopic guidance. Barium opacified polymethylmethacrylate cement (Osteopal®V, Hereus, Germany or OsteoFirm, William Cook Europe, Denmark) was injected using Duro-Ject® Vertebroplasty Injector Set (William Cook) under fluoroscopic guidance. The procedure was discontinued when the cement reached the dorsal quarter of the vertebral body or when epidural or venous extravasation was observed. In the case of recent multiple fractures, each vertebra with a STIR hypersignal was treated during a single anesthesiologic procedure. Outpatient physiotherapy (in a non-specialized clinic chosen by the participant) began on the tenth day postop and included massage, strengthening of the core muscles (abdominals and spinal muscles), pelvic tilting, stretching of the sub-pelvic muscles and general exercise. The intensity and duration of the rehabilitation was at the discretion of the physiotherapist.

### **Bracing**

Bracing consisted of tailor-made polypropylene rigid thoraco-lumbo-sacral orthoses (TLSO) with an anterior opening and velcro straps for fastening. The TLSO was modelled on a positive plaster mold of the participant. The participants were kept in strict supine lying while waiting to

receive the brace. Once delivered, the brace was donned every morning with the participant in supine, before rising and was worn all day long for 3 months.

Toileting was performed in bed by a nurse. Outpatient physiotherapy (in a non-specialized clinic chosen by the participant) began immediately after reception of the brace and included isometric work of the extensor muscles of the spine for 3 months and dynamic work after brace removal. The intensity and duration of the rehabilitation was at the discretion of the physiotherapist.

### **Outcome assessment**

The primary outcome was the between-group difference in back pain related functional disability at 1 month, measured using the modified Roland–Morris Disability Questionnaire (RMDQ) [15].

The RMDQ is a 21-item, self-report questionnaire about how low-back pain affects functional activities. Each question is worth 1 point and scores range from 0 (no disability) to 24 (severe disability). The original questionnaire and all translations are freely available. The minimal clinically important difference for this questionnaire is reported to be 3 to 5 points after 3 to 6 weeks of treatment [16,17].

Secondary outcomes included the assessment of the following criteria at day 2, and 1, 3 and 6 months after the procedure: pain using a visual analog scale of 0 to 10 (0 indicating no pain and 10 the maximum intensity of pain), functional outcome using the RMDQ scale, health-related quality of life using the Medical Outcome Study Short Form-36 (SF-36), including the mental and physical component summaries.

The SF-36 questionnaire rates health-related quality of life on 8 domains with scores ranging from 0 (poor quality of life) to 100 (satisfactory quality of life): physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These domains can be regrouped into 2 distinct concepts: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS). All scales contribute to the scoring of both PCS and MCS measures in different proportions. The minimum clinically important difference for the SF-36 is 4.9 points [18].

Painkiller consumption and number of days off work were collected at each follow-up visit.

Morphological changes were assessed by comparing anterior and posterior vertebral body height and local kyphosis angle (LKA) to pretreatment measures. LKA was defined as the angle formed by the upper endplate of the vertebra overlying the fracture and the lower endplate of the vertebra underlying the fracture. In the case of multiple fractures adjacent to the fracture, the LKA was defined as the angle between the upper vertebral endplate of the most cranial non-fractured vertebra and the lower endplate of the most caudal non-fractured vertebra (Figure 1). In the case of multiple non-adjacent fractures, the LKA was not calculated. Initial anatomical measurements were performed on the pre therapeutic CT-scan. Within 2 days of treatment, bracing was checked by X-Ray and vertebroplasty by CT scan. At 1 month a CT-scan was performed. At 3 and 6 months, a radiological assessment was performed using standing lateral spinal X-Ray. Measurements were made by 3 neuroradiologists (EC, EH and AK).

### **Sample size calculation**

The study was initially powered to detect a 3-point difference between the groups with an assumed SD of 6 for a two-sided  $\alpha=0.05$  and a statistical power of 80% [19,20]. Considering possible crossovers and losses to follow-up the sample size was fixed at 70 participants in each group. After the planned interim analysis, we reduced the target sample size to 100

participants after approval of the independent data and safety monitoring board. The decision to modify the target sample size was primarily driven by accrual rates and revised power calculations. The board used O'Brien–Fleming stopping rules of  $p < 0.015$  for prespecified interim analyses to evaluate the accumulating evidence of treatment efficacy. After 100 inclusions, the statistical significance of the between-group difference for the primary objective led us to stop the enrollment. One participant with incomplete data was removed from the study, therefore the overall sample consisted of 99 participants.

### **Randomization**

Individuals with one or several acute compression fractures were randomly assigned to undergo vertebroplasty or bracing. Stratified randomization according to age was performed in both groups to achieve balanced groups. Randomization by random block sizes was performed using Stata software (StataCorp, Texas, USA).

### **Statistical analysis**

Univariate analyses were conducted. For the primary analyses, we used a modified intention-to-treat strategy with participants analyzed in their assigned group. A sensitivity analysis was also performed in the intention-to-treat population with an imputation data approach (Last Observation Carried Forward method). The per-protocol population was also analyzed, focusing only on participants with available data at all evaluation time-points. An unadjusted Student t test was used for the primary outcome analysis. Secondly, the treatment effect was estimated using linear regression models with adjustment for baseline values of the outcome measure, stratification variables and clinically relevant parameters: sex, age, other lesions and number of spinal levels treated. Other continuous variables were compared using the unpaired Student t test or the Mann–Whitney U test. The Shapiro-Wilk test was used to assess the normality of the distributions, and the Fisher-Snedecor test to assess homoscedasticity. Results are reported as effect-sizes and 95% confidence intervals. Unadjusted chi-square or

Fisher exact tests were used for comparisons of categorical data. Random-effects models were performed to take into account within- and between-participant variability (as a random effect) to analyze longitudinal data with adjustment for the baseline values of the outcome measures. The following fixed effects were analyzed: randomization group, evaluation time-point, and their interaction. The normality of residuals from these models was checked as described above. Because fewer than 5% of data were missing or unavailable, procedures for handling of missing data were not applied. Analyses were performed using Stata version 13.0 (StataCorp LP, College Station, TX, USA). A two-sided p-value of less than 0.05 was considered to indicate statistical significance (except for the primary outcome analysis).

## **RESULTS**

### Participants

Of the 260 potential participants admitted between September 2010 and September 2012, 99 met the inclusion criteria and were randomized: 51 to the vertebroplasty group and 48 to the brace group (Figure 2). The study was initially designed to include 140 participants, but the statistically significant difference between groups for the primary outcome after the inclusion of 99 participants led us to stop the enrollment. Mean (SD) age of participants in the brace group was 45.3 (17.2) years and 44.5 (16.9) years in the vertebroplasty group. Age distribution according to group is shown in Figure A. In total, 60% of the fractures were A.1 type according to Magerl classification (Tables 1 and 2). One participant assigned to the brace group underwent a secondary vertebroplasty because of sustained pain at the 1-month assessment and was therefore considered as a crossover. No participants treated with vertebroplasty received braces. The baseline characteristics of the groups were similar (Table 1). At 1 month, 100 % of the participants underwent a clinical and radiological assessment. At 6 months,

complete data were available for 84 participants (88%) since 10 participants in the brace group and 4 in the vertebroplasty group were lost to follow-up.

### Treatment

The time from trauma to treatment ranged from 1 to 12 days (mean, SD: 4, 2.4 days) with no difference between groups. In total, 13 participants (28%) in the brace and 14 (27%) in the vertebroplasty group received treatment for more than 1 spinal level. In the vertebroplasty group, participants received injections of a mean (SD) 6 (2) ml of cement (range 2.5 to 13 ml). Cement placement via a contralateral extrapedicular approach was never necessary.

### Functional disability

The results are summarized in Table 3 and illustrated in Figure 3. RMDQ score at 1 month was significantly lower in the vertebroplasty than the brace group: mean (SD) 7.5 (5.7) points vs 11.4 (5.3);  $p < 0.001$ . These results were not influenced by the type of fracture. This superiority decreased gradually throughout the 6 months of follow up: 5 (5.2) vs 3.2 (4.6);  $p = 0.06$ . SF-36 scores improved throughout the follow-up, the physical component score of the vertebroplasty group tended to be higher than that of the brace group at 6 months: 68.5 (24.9) vs 58.3 (22.1);  $p = 0.03$ . RMDQ score at 3 months was significantly lower (ie, improved) than at 6 months for both groups. The results of the per-protocol analysis confirmed those of the intention-to-treat analysis.

RMDQ score at 1 month did not differ between age groups: 10.4 (5.6) (vertebroplasty group) vs 7.0 (5.9) (brace group) for participants  $\geq 50$  years old, and 12.5 (4.8) (vertebroplasty group) vs 8.1 (5.5) (brace group) for participants  $< 50$  years old ( $p = 0.80$ ). The length of hospital stay did not differ between groups: 3.9 (1.6) days in the vertebroplasty group and 3.5 (1.3) days in the brace group ( $p = 0.22$ ). Time to return to work tended to be longer in the brace group than

in the vertebroplasty group, but the difference was not statistically significant (105 vs 90 days;  $p=0.19$ ).

### Pain

There was no between group difference in pain at inclusion (Table A). At day 2, the VAS pain rating was 1.1 points lower in the vertebroplasty group than the brace group: 3.4 (2.1) vs 2.3 (1.5);  $p=0.004$ . The results of the per-protocol analysis confirmed those of the intention-to-treat analysis. The results are summarized in Table 3 and illustrated in Figure 3.

At day 2, VAS pain rating was > 3 points in 60% of participants in the brace group and 40 % in the vertebroplasty group ( $p=0.09$ ). No between-group differences were found for VAS pain rating at 1, 3 and 6 months. However, the number of participants using opioid drugs at 3 months was significantly lower in the vertebroplasty group than the brace group (6% vs 23%;  $p=0.02$ ). Moreover, the VAS pain rating for the brace group decreased progressively and significantly from 1 month to 6 months. Opioid consumption was not conditioned by participant age.

### Radiological assessment

Significant between-group differences were found in anatomical changes of the spine. At day 2, anterior vertebral body height was slightly restored in the vertebroplasty group but not in the brace group: +1.2 (4.3) mm;  $p\leq 0.001$ , vs -0.5 (0.7) mm;  $p=0.003$ . At 6 months, the decrease in anterior vertebral body height was significantly smaller in the vertebroplasty group than the bracing group: 0.1 (0.7) mm vs -2.5 (0.5) mm,  $p\leq 0.001$ ; whereas the change in posterior vertebral body height was identical in both groups: -0.4 mm (1.5). At 2 days, the LKA slightly decreased after vertebroplasty but increased after bracing:  $-0.7^\circ$  (0.3) vs  $+1^\circ$  (0.1),  $p=0.005$ . At 6 months, the increase in kyphosis angle (from pre-treatment values) was smaller in the vertebroplasty than the brace group:  $+1.5^\circ$  (4.9);  $p<0.001$  vs  $+4^\circ$  (12.9);  $p<0.001$ . The kyphosis

angle increased and the anterior wall height decreased progressively at each follow-up (day 2, 1 month, 2 months and 3 months), ( $p=0.005$ ). The results of the per-protocol analysis confirmed those of the intention-to-treat analysis. The results are summarized in Table 3 and illustrated in Figure 3.

### Complications

No clinical complications were reported in either group. In the vertebroplasty group, cement leakage with no clinical consequences occurred in 30 cases (57%). No cement leakage occurred in the vertebral canal, the leakages occurred in the intervertebral disc (11/30), in the perivertebral veins (10/30) and in the perivertebral spaces (9/30). No additional compression fractures in adjacent vertebrae were reported over the 6-month follow-up period in either group.

## **DISCUSSION**

This study showed that functional outcome, measured by the RMDQ, was better after vertebroplasty than bracing in people with acute vertebral compression fractures. The RMDQ score was 3.8 (95% CI, -5.96 to -1.56) points lower (indicating better function) at 1 and 3 months in the vertebroplasty than the brace group.

The RMDQ scores of the brace group were 11.4, 7.6 and 5 at 1, 3 and 6 months respectively. The RMDQ scores of the vertebroplasty group, were 7.5, 3.8 and 3.2 at 1, 3 and 6 months respectively. A change between 3 and 5 points has been suggested as the smallest change after 3 to 6 weeks of treatment. We considered that the 3-point difference in RMDQ in sample size estimation (for a moderate effect-size of 0.5) guaranteed a minimal satisfactory sample size. Indeed, for a 3-point difference, 63 participants were needed per group whereas only 23

participants per group were necessary for a 5-point difference, with a two-sided type I error at 5% and 80% statistical power. The per-protocol analysis of the data confirmed this finding, and these values are consistent with the data from previous studies of bracing [2,6] and vertebroplasty [21,22].

Analgesia was adjusted on day 2 in both groups. However, the VAS score in the vertebroplasty group was more than 1 point lower than in the brace group (2.3 vs 3.4;  $p=0.004$ ). This difference is clinically relevant since the minimal clinically important difference for VAS pain ratings is 0.9 to 1.6 points [23,24]. However, the effect size was -0.59 (95% CI -0.18 to -0.99), which is considered moderate according to Cohen [25]. At months 1, 3 and 6, there was no difference between the groups despite the significant between-group difference in functional outcome. This apparent discrepancy between changes over time in RMDQ scores and pain ratings could be explained by the fact that the disability assessed by the RMDQ score is not only related to pain but also to overall mobility. The RMDQ score might also be a better global indicator of pain status than the VAS rating alone. Outcomes explored by the RMDQ score are multidimensional whereas pain intensity is only one component of this evaluation. In addition, pain is a multidimensional experience whereas the VAS is a one-dimensional instrument of assessment. The superiority of vertebroplasty over bracing was greater at the first assessment time-point (day 2) for both functional outcome and pain relief. Vertebroplasty is a minimally invasive technique that provides immediate stability and enables rapid mobilization of the individual. When professional and social activities are resumed, participants are not impeded in their movements, in contrast with bracing that limits movement amplitudes.

Although the study was randomized, participants could not be blinded to the treatment they received. Invasive procedures such as vertebroplasty may lead to higher expectations and may be associated with a greater placebo effect than bracing, which may have influenced the results [26]. However, the change in pain over time differed between the groups; it decreased progressively and significantly in the brace group but not in the vertebroplasty group. This is because of the greater immediate analgesic effect of vertebroplasty, which was also long-

lasting. The improvement in function in the brace group was related to the decrease in pain. Indeed, the SF-36 mental health score did not increase significantly over time. This may be due to the physical limitations caused by the brace. One could therefore assume that the between-group differences in RMDQ score are the consequences of simply wearing a brace.

In the vertebroplasty group, anterior vertebral body height increased slightly just after the procedure was performed and remained stable over the 6-month follow-up. This kyphoplasty-like effect was intentionally obtained by placing cushions under the hips and upper thorax. Conversely, in the brace group, the vertebral body height decreased over time. This finding suggests that vertebroplasty could be more effective than bracing in preserving vertebral body height, even if vertebroplasty should not be expected to restore vertebral body height to the same extent as kyphoplasty [27-29]. A synergy between the hyperlordosis, resulting from the positioning, and the injection of cement which consolidates it, could explain this structural effect. LKA increased to a greater extent in the brace group ( $+4^\circ$  vs  $+1.5^\circ$  at 6 months). The increase in LKA in both groups may be partially explained by a disc collapse that might have worsened the effect of anterior vertebral body compression. Indeed, in Magerl A fractures, damage to the vertebral endplate occurs in association with the disc damage. A collapsing disc can lead to an increase in LKA despite conservation of vertebral body height. This would explain the initial moderate worsening of the LKA for the vertebroplasty group, despite preserved vertebral height. Moreover, LKA and vertebral height remained stable over time in the vertebroplasty group. In contrast, LKA increased, and vertebral height decreased over time in the brace group. The latter results are in favor of the superiority of vertebroplasty. However, one limitation in the interpretation of these results is that the assessor could not be blinded to group allocation when performing the anatomical measurements because cement is radiopaque.

The percentage of cement leakage (57%) was similar to that reported by previous studies of vertebroplasty performed for the usual indications, osteoporotic compression fractures and malignant disease [30-32]. Like tumors, acute high energy traumatic fractures may lead to

endplate damage, increasing the risk of leakage into the vertebral canal since the cement sinks into the interstices between bony fragments and exits the vertebra. In most cases, cement leakages have no clinical consequences [32,33]. We decided not to perform bone densitometry to avoid mobilizing the fracture or delaying the treatment. Some participants may therefore have had osteoporosis. However, the randomization should have ensured an even distribution of such participants in each arm. In addition, the age distribution was equivalent in each group. Therefore, there was no over-representation of older adults, who are more likely to have osteoporosis, in any group. Moreover, no additional compression fracture was observed in adjacent vertebrae after treatment (brace or vertebroplasty), which may indicate a low proportion of osteoporosis in the sample.

## **CONCLUSION**

Our study demonstrated a moderately greater efficacy of vertebroplasty over bracing in terms of functional outcome and pain after acute vertebral compression fractures. Moreover, the superiority of vertebroplasty over bracing was particularly evident early after the procedure, which may lead to an earlier resumption of professional activities. Vertebroplasty also provided greater prevention of ongoing vertebral collapse and kyphosis than bracing.

## **Acknowledgements**

We thank Stephane Dalet and Vera Gwidz, computer engineers for their involvement in data collection. We thank Bertille Lamande clinical research associate for the supervision of participants.

**Conflict of interest:** none

**Funding:** Funding was allocated by University Hospital of Clermont-Ferrand for the payment of the clinical research associate.

**Figure 1.** Local kyphosis angle (LKA) calculation method in case of a single vertebral compression fracture (a) and in case of multiple vertebral compression fractures (b).

**Figure 2.** VOLCANO flow diagram of participation

**Figure 3.** Clinical and anatomical outcomes. Clinical outcomes included the score on the Roland–Morris Disability Questionnaire (RMDQ), the Visual Analog Scale (VAS), and the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) Physical Component Summary and Mental Component Summary. Anatomical outcomes included anterior vertebral body height and local kyphosis angle. D2 = 2<sup>nd</sup> day postop, M1 = 1 month, M3 = 3 months and M6 = 6 months.

**Figure A:** Age distribution according to vertebroplasty or brace group. The distribution by age group is comparable in the two groups. Mean age was 45.3 (SD 17.2) in the brace group and 44.5 (SD16.9) in the vertebroplasty group.

## References

- [1] Zaryanov AV, Park DK, Khalil JG, Baker KC, Fischgrund JS. Cement augmentation in vertebral burst fractures. *Neurosurg Focus* 2014;37:E5. <https://doi.org/10.3171/2014.5.FOCUS1495>.
- [2] Bailey CS, Dvorak MF, Thomas KC, Boyd MC, Paquett S, Kwon BK, et al. Comparison of thoracolumbosacral orthosis and no orthosis for the treatment of thoracolumbar burst fractures: interim analysis of a multicenter randomized clinical equivalence trial. *J Neurosurg Spine* 2009;11:295–303. <https://doi.org/10.3171/2009.3.SPINE08312>.
- [3] Marco RAW, Kushwaha VP. Thoracolumbar burst fractures treated with posterior decompression and pedicle screw instrumentation supplemented with balloon-assisted vertebroplasty and calcium phosphate reconstruction. *J Bone Joint Surg Am* 2009;91:20–8. <https://doi.org/10.2106/JBJS.G.01668>.
- [4] Shamji MF, Roffey DM, Young DK, Reindl R, Wai EK. A Pilot Evaluation of the Role of Bracing in Stable Thoracolumbar Burst Fractures Without Neurologic Deficit. *J Spinal Disord Tech* 2012. <https://doi.org/10.1097/BSD.0b013e31826eacae>.
- [5] Oner FC, Wood KB, Smith JS, Shaffrey CI. Therapeutic decision making in thoracolumbar spine trauma. *Spine* 2010;35:S235-244. <https://doi.org/10.1097/BRS.0b013e3181f32734>.
- [6] Wood K, Buttermann G, Buttermann G, Mehbod A, Garvey T, Jhanjee R, et al. Operative compared with nonoperative treatment of a thoracolumbar burst fracture without neurological deficit. A prospective, randomized study. *J Bone Joint Surg Am* 2003;85-A:773–81.
- [7] Costa F, Ortolina A, Cardia A, Sassi M, De Santis A, Borroni M, et al. Efficacy of treatment with percutaneous vertebroplasty and kyphoplasty for traumatic fracture of thoracolumbar junction. *J Neurosurg Sci* 2009;53:13–7.
- [8] Schmelzer-Schmied N, Cartens C, Meeder PJ, Dafonseca K. Comparison of kyphoplasty with use of a calcium phosphate cement and non-operative therapy in patients with traumatic non-osteoporotic vertebral fractures. *Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc* 2009;18:624–9. <https://doi.org/10.1007/s00586-008-0880-x>.
- [9] Noriega D, Krüger A, Ardura F, Hansen-Algenstaedt N, Hassel F, Barreau X, et al. Clinical outcome after the use of a new craniocaudal expandable implant for vertebral compression fracture treatment: one year results from a prospective multicentric study. *BioMed Res Int* 2015;2015:927813. <https://doi.org/10.1155/2015/927813>.
- [10] Chen J-F, Lee S-T. Percutaneous vertebroplasty for treatment of thoracolumbar spine bursting fracture. *Surg Neurol* 2004;62:494–500. <https://doi.org/10.1016/j.surneu.2003.10.049>.

- [11] Huet H, Cabal P, Gadan R, Borha A, Emery E. Burst-fractures and cementoplasty. *J Neuroradiol* 2005;32:33–41.
- [12] Elnoamany H. Percutaneous vertebroplasty: a first line treatment in traumatic non-osteoporotic vertebral compression fractures. *Asian Spine J* 2015;9:178–84. <https://doi.org/10.4184/asj.2015.9.2.178>.
- [13] Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P, CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Ann Intern Med* 2017;167:40–7. <https://doi.org/10.7326/M17-0046>.
- [14] Long SS, Yablon CM, Eisenberg RL. Bone marrow signal alteration in the spine and sacrum. *AJR Am J Roentgenol* 2010;195:W178-200. <https://doi.org/10.2214/ajr.09.4134>.
- [15] Trout AT, Kallmes DF, Gray LA, Goodnature BA, Everson SL, Comstock BA, et al. Evaluation of vertebroplasty with a validated outcome measure: the Roland-Morris Disability Questionnaire. *AJNR Am J Neuroradiol* 2005;26:2652–7.
- [16] Ostelo RWJG, de Vet HCW. Clinically important outcomes in low back pain. *Best Pract Res Clin Rheumatol* 2005;19:593–607. <https://doi.org/10.1016/j.berh.2005.03.003>.
- [17] Stratford PW, Binkley J, Solomon P, Finch E, Gill C, Moreland J. Defining the minimum level of detectable change for the Roland-Morris questionnaire. *Phys Ther* 1996;76:359–65; discussion 366-368. <https://doi.org/10.1093/ptj/76.4.359>.
- [18] Copay AG, Glassman SD, Subach BR, Berven S, Schuler TC, Carreon LY. Minimum clinically important difference in lumbar spine surgery patients: a choice of methods using the Oswestry Disability Index, Medical Outcomes Study questionnaire Short Form 36, and pain scales. *Spine J Off J North Am Spine Soc* 2008;8:968–74. <https://doi.org/10.1016/j.spinee.2007.11.006>.
- [19] Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. *N Engl J Med* 2009;361:569–79. <https://doi.org/10.1056/NEJMoa0900563>.
- [20] Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. *N Engl J Med* 2009;361:557–68. <https://doi.org/10.1056/NEJMoa0900429>.
- [21] Huet H, Cabal P, Gadan R, Borha A, Emery E. Burst-fractures and cementoplasty. *J Neuroradiol* 2005;32:33–41; discussion 41. [https://doi.org/10.1016/s0150-9861\(05\)83019-6](https://doi.org/10.1016/s0150-9861(05)83019-6).
- [22] Elnoamany H. Percutaneous vertebroplasty: a first line treatment in traumatic non-osteoporotic vertebral compression fractures. *Asian Spine J* 2015;9:178–84. <https://doi.org/10.4184/asj.2015.9.2.178>.
- [23] Todd KH. Patient-oriented outcome measures: the promise of definition. *Ann Emerg Med* 2001;38:672–4. <https://doi.org/10.1067/mem.2001.119746>.
- [24] Kelly AM. The minimum clinically significant difference in visual analogue scale pain

score does not differ with severity of pain. *Emerg Med J EMJ* 2001;18:205–7.

[25] Cohen J. *Statistical power analysis for the behavioral sciences* (Revised ed.). Hillsdale, NJ: Lawrence Earlbaum Associates 1988.

[26] Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. *Ann Intern Med* 2002;136:471–6.

[27] Blondel B, Fuentes S, Pech-Gourg G, Adetchessi T, Tropiano P, Dufour H. Percutaneous management of thoracolumbar burst fractures: Evolution of techniques and strategy. *Orthop Traumatol Surg Res OTSR* 2011;97:527–32. <https://doi.org/10.1016/j.otsr.2011.03.020>.

[28] Maestretti G, Sutter P, Monnard E, Ciarpaglini R, Wahl P, Hoogewoud H, et al. A prospective study of percutaneous balloon kyphoplasty with calcium phosphate cement in traumatic vertebral fractures: 10-year results. *Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc* 2014;23:1354–60. <https://doi.org/10.1007/s00586-014-3206-1>.


[29] Piazzolla A, De Giorgi S, Solarino G, Mori C, De Giorgi G. Vertebral body reconstruction system B-Twin® versus corset following non-osteoporotic Magerl A1.2 thoracic and lumbar fracture. Functional and radiological outcome at 12 month follow-up in a prospective randomized series of 50 patients. *Orthop Traumatol Surg Res OTSR* 2011;97:846–51. <https://doi.org/10.1016/j.otsr.2011.08.006>.

[30] Cotten A, Dewatre F, Cortet B, Assaker R, Leblond D, Duquesnoy B, et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up. *Radiology* 1996;200:525–30. <https://doi.org/10.1148/radiology.200.2.8685351>.


[31] Hodler J, Peck D, Gilula LA. Midterm outcome after vertebroplasty: predictive value of technical and patient-related factors. *Radiology* 2003;227:662–8. <https://doi.org/10.1148/radiol.2273011930>.

[32] Capel C, Fichten A, Nicot B, Lefranc M, Toussaint P, Desenclos C, et al. Should we fear cement leakage during kyphoplasty in percutaneous traumatic spine surgery? A single experience with 76 consecutive cases. *Neurochirurgie* 2014;60:293–8. <https://doi.org/10.1016/j.neuchi.2014.05.004>.

[33] Khosla A, Diehn FE, Rad AE, Kallmes DF. Neither subendplate cement deposition nor cement leakage into the disk space during vertebroplasty significantly affects patient outcomes. *Radiology* 2012;264:180–6. <https://doi.org/10.1148/radiol.12112215>.



a



b

# VOLCANO flow diagram

Enrollment

Assessed for eligibility  
(n = 260)

Excluded (n = 161)

- Not meeting inclusion criteria (n = 152)
- Refused to participate (n=9)

Randomized (n = 99)

Allocation

Allocated to bracing (n = 48)

Received bracing (n = 48)

- One cross-over from bracing to vertebroplasty at <3 month

Allocated to vertebroplasty (n = 51)

Received vertebroplasty (n = 52)

- One cross-over from bracing to vertebroplasty at <3 month

Follow-up

1 month assessment:

- lost to follow-up (n = 0)

3 month assessment :

- lost to follow-up (n = 4)

6 month assessment :

- lost to follow-up (n = 6)

1 month assessment:

- lost to follow-up (n = 0)

3 month assessment :

- lost to follow-up (n = 1)

6 month assessment :

- lost to follow-up (n = 3)

Analysis

Analysed

- 1 month (n = 47)
- 3 month (n = 43)
- 6 month (n = 37)





Excluded from analysis (n = 0)

Analysed

- 1 month (n = 51)
- 3 month (n = 51)
- 6 month (n = 47)

Excluded from analysis (n = 0)

# Clinical outcomes



# Anatomical outcomes





Table 1 Baseline Characteristics

	Brace (n=48)	Vertebroplasty (n=51)
Age >55 years, no. (%)	21 (44)	21 (41)
Mean age (SD)	45.3 (17.2)	44.5 (16.9)
Male sex, no. (%)	35 (73)	30 (59)
Spinal levels treated >1, no. (%)	13 (28)	14 (27)
Fracture type (Magerl's), no. (%)		
A1.1, A1.2, A1.3	26 (54)	33 (65)
A2.1, A2.2, A2.3	6 (12)	6 (12)
A3.1, A3.2, A3.3	16 (33)	12 (23)
Other lesions*, no. (%)	7 (15)	12 (23)
RMDQ score, mean (SD)	23.8 (1)	23.7 (1.5)
Pain intensity, mean (SD)	6.7 (1.9)	6.7 (2.2)
SF36		
Mental Health, mean (SD)	73.1 (23.3)	72.8 (20.7)
Physical Health, mean (SD)	69.3 (27.3)	73.1 (25.6)
Time from trauma to treatment days, mean (SD)	4.0 (1.9)	3.9 (2.7)

RMDQ Roland-Morris disability questionnaire, SF36 Medical Outcome Study Short Form-36, \*extra-spinal traumatic injuries.

Table 2 Number of participants with each fracture type (Magerl classification) and fracture location

Magerl type	Fracture location													TOTAL
	T5	T6	T7	T8	T9	T10	T11	T12	L1	L2	L3	L4	L5	
A1.1			1	2	1		4	6	5	5	2	1		27
A1.2		2	1	5	3	1	5	9	16	5	3	4	2	56
A1.3		1	1	1	1			4	6	1	2	1		18
A2.1								1		1				2
A2.2										1	1	1		3
A2.3								1	4		2			7
A3.1	1		1		2		1	8	10	3				26
A3.2				1				1	1					3
A3.3														0
TOTAL	1	3	4	9	7	1	10	30	42	16	10	7	2	142

Table 3 Clinical and anatomical outcomes (univariate analyses)

	Brace	Vertebroplasty	ES (95% CI), p-value
<b>Clinical outcomes</b>			
RMDQ, mean (SD) - ITT with imputation data (LOCF)			
M1 (n=48/51)	11.4 (5.3)	7.5 (5.7)	-0.70 (-1.11 to -0.30), p<0.001
M3 (n=48/51)	7.6 (6.0) ***	3.8 (4.3) ***	-0.72 (-1.11 to -0.31), p<0.001
M6 (n=48/51)	5.0 (5.2) ***	3.2 (4.6) ***	-0.37 (-0.77 to 0.02), p=0.06
RMDQ, mean (SD) - per-protocol			
M1 (n=37/47)	11.6 (4.9)	7.1 (5.3)	-0.86 (-1.31 to -0.42), p<0.001
M3 (n=37/47)	7.6 (6.0)	3.6 (3.9)	-0.80 (-1.25 to -0.36), p<0.001
M6 (n=37/47)	4.3 (4.6)	2.9 (4.2)	-0.33 (-0.76 to -0.10), p=0.14
Pain intensity, mean (SD) - ITT with imputation data (LOCF)			
D2 (n=46/51)	3.4 (2.1)	2.3 (1.5)	-0.59 (-0.18 to -0.99), p=0.004
M1 (n=48/51)	1.9 (2.1) ***	2.4 (1.9)	0.24 (-0.16 to 0.63), p=0.24
M3 (n=48/51)	1.6 (1.9) ***	1.6 (1.9) *	0.00 (-0.39 to 0.39), p=0.99
M6 (n=48/51)	1.8 (1.9) ***	1.4 (1.8) **	-0.21 (-0.60 to 0.18), p=0.30
Pain intensity, mean (SD) - per-protocol			
D2 (n=37/47)	3.4 (1.9)	2.2 (1.6)	-0.63 (-1.07 to -0.18), p=0.006
M1 (n=37/47)	1.5 (1.6)	2.3 (2.0)	0.43 (-0.01 to 0.87), p=0.06
M3 (n=37/47)	1.6 (1.9)	1.5 (1.8)	-0.05 (-0.48 to 0.38), p=0.82
M6 (n=37/47)	1.8 (2.0)	1.3 (1.6)	-0.28 (-0.71 to 0.16), p=0.21
SF36 Mental Health, mean (SD) - ITT with imputation data (LOCF)			
M1 (n=48/50)	50.2 (20.6)	52.5 (20.1)	0.11 (-0.28 to 0.50), p=0.58
M3 (n=48/51)	53.8 (19.9)	63.4 (21.3) ***	0.46 (0.07 to 0.86), p=0.02
M6 (n=48/51)	64.5 (21.9) ***	71.7 (23.1) ***	0.32 (-0.08 to 0.71), p=0.12
SF36 Mental Health, mean (SD) - per-protocol			
M1 (n=37/47)	49.0 (20.6)	54.4 (20.0)	0.26 (-0.17 to 0.69), p=0.24
M3 (n=37/47)	53.9 (19.2)	64.8 (20.6) ***	0.54 (0.10 to 0.98), p=0.02
M6 (n=37/47)	67.5 (20.5) ***	74.8 (21.7) ***	0.34 (-0.09 to 0.78), p=0.12
SF36 Physical Health, mean (SD) - ITT with imputation data (LOCF)			
M1 (n=48/50)	38.5 (11.7)	44.8 (16.8)	0.43 (0.03 to 0.83), p=0.03
M3 (n=48/51)	49.3 (18.5) ***	29.4 (21.9) ***	0.49 (0.09 to 0.89), p=0.02
M6 (n=48/51)	58.3 (22.1) ***	68.5 (24.9) ***	0.43 (0.03 to 0.82), p=0.03
SF36 Physical Health, mean (SD) - per-protocol			
M1 (n=37/47)	38.3 (10.1)	46.2 (16.3)	0.56 (0.12 to 1.00), p=0.01
M3 (n=37/47)	50.6 (17.2) ***	61.1 (21.3) ***	0.53 (0.10 to 0.97), p=0.02
M6 (n=37/47)	62.2 (20.7) ***	72.3 (23.6) ***	0.45 (0.01 to 0.88), p=0.04

---

## **Anatomical outcomes**

### LOCAL KYPHOSIS ANGLE (°), mean (SD) - ITT with imputation data (LOCF)

Inclusion (N=37/39)	10.7 (7.0)	10.8 (6.2)	Baseline value
D2 (N=40/39)	11.7 (7.1) *	10.1 (5.9)	-0.23 (-0.67 to 0.21), p=0.30
M1 (N=41/39)	13.5 (7.3) ***	11.5 (6.6)	-0.28 (-0.72 to 0.16), p=0.21
M3 (N=41/39)	14.7 (7.8) ***	11.9 (7.1) *	-0.36 (-0.80 to 0.08), p=0.11
M6 (N=41/39)	14.7 (8.3) ***	12.3 (7.3) ***	-0.30 (-0.74 to 0.14), p=0.18

### LOCAL KYPHOSIS ANGLE (°), mean (SD) - per-protocol

Inclusion (N=37/39)	10.7 (7.0)	10.8 (6.2)	Baseline value
D2 (N=33/36)	12.3 (7.4) *	10.5 (5.8)	-0.26 (-0.72 to 0.21), p=0.28
M1 (N=39/37)	13.7 (7.4) ***	12.0 (6.4)	-0.24 (-0.69 to 0.21), p=0.31
M3 (N=32/38)	15.7 (8.1) ***	12.5 (7.0)	-0.44 (-0.91 to 0.03), p=0.08
M6 (N=28/35)	15.0 (8.5) ***	12.9 (7.4)	-0.31 (-0.80 to 0.18), p=0.30

---

### ANTERIOR HEIGHT (mm), mean (SD) - ITT with imputation data (LOCF)

Inclusion (N=44/51)	21.8 (3.9)	21.5 (4.1)	Baseline value
D2 (N=47/51)	21.3 (4.6) **	22.7 (4.4) ***	0.30 (-0.10 to 0.69), p=0.14
M1 (N=48/51)	20.1 (4.6) ***	21.8 (4.6)	0.39 (0.00 to 0.79), p=0.05
M3 (N=48/51)	19.4 (4.6) ***	21.5 (4.6)	0.48 (0.08 to 0.88), p=0.02
M6 (N=48/51)	19.3 (4.4) ***	21.6 (4.8)	0.49 (0.09 to 0.88), p=0.02

### ANTERIOR HEIGHT (mm), mean (SD) - per-protocol

Inclusion (N=44/51)	21.8 (3.9)	21.5 (4.1)	Baseline value
D2 (N=41/49)	21.2 (4.8) **	22.6 (4.4) **	0.30 (-0.11 to 0.71), p=0.16
M1 (N=45/51)	20.1 (4.7) ***	21.8 (4.6)	0.40 (-0.01 to 0.80), p=0.06
M3 (N=41/51)	19.3 (4.9) ***	21.5 (4.7)	0.50 (0.08 to 0.91), p=0.03
M6 (N=36/48)	19.4 (4.6) ***	21.3 (4.8)	0.45 (-0.02 to 0.88), p=0.07

---

### POSTERIOR HEIGHT (mm), mean (SD) - ITT with imputation data (LOCF)

Inclusion (N=44/51)	26.5 (3.2)	26.6 (3.6)	Baseline value
D2 (N=47/51)	26.7 (3.8)	26.6 (3.6)	-0.03 (-0.43 to 0.36), p=0.86
M1 (N=48/51)	26.6 (3.9)	26.6 (3.5)	0.01 (-0.38 to 0.40), p=0.95
M3 (N=48/51)	26.6 (4.0)	26.5 (3.7)	-0.02 (-0.41 to 0.37), p=0.91
M6 (N=48/51)	26.3 (4.0)	26.3 (3.6) *	0.00 (-0.39 to 0.39), p=0.99

### POSTERIOR HEIGHT (mm), mean (SD) - per-protocol

Inclusion (N=44/51)	26.5 (3.2)	26.6 (3.6)	Baseline value
D2 (N=41/49)	26.9 (3.9)	26.5 (3.6)	-0.09 (-0.50 to 0.32), p=0.56
M1 (N=45/51)	26.6 (4.0) *	26.6 (3.5)	0.02 (-0.37 to 0.42), p=0.98
M3 (N=41/51)	26.8 (4.3)	26.5 (3.7)	-0.04 (-0.45 to 0.36), p=0.72
M6 (N=36/48)	26.1 (3.4) **	26.2 (3.7)	0.07 (-0.36 to 0.50), p=0.85

---

ITT Intention-To-Treat, LOCF Last Observation Carried Forward method, RMDQ Roland Morris Disability Questionnaire

\*p≤0.05, \*\*p≤0.01, \*\*\*p≤0.001: p-values for within-group comparisons.

ES (95%CI), p-value: effect-size, 95% confidence interval and p-value for between-group comparisons.